Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy

Completed

Conditions studied: Breast Neoplasms

In brief

The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.

Key facts

Study ID

NCT00146536

Run by

Dana-Farber Cancer Institute

People needed

78

Starts

2004-11-01

Expected to finish

2012-11-01

Last updated by the study team

2017-03-31

Who can join

Age: 20 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women 20 years of age or older
• Imaging abnormality necessitating a core needle biopsy
• Core needle biopsy revealing ALH or LCIS
• Patients may have a history of fibroadenoma and/or proliferative breast lesions with atypia

You may not qualify if…

• History and/or concomitant diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS)
• A palpable abnormality diagnosed by core needle biopsy to be ALH or LCIS
• Received tamoxifen in the past

Where it is running

• Dana-Farber Cancer Center — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.